MML Investors Services LLC Buys 6,018 Shares of Moderna, Inc. (NASDAQ:MRNA)

MML Investors Services LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 21.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 33,895 shares of the company’s stock after purchasing an additional 6,018 shares during the quarter. MML Investors Services LLC’s holdings in Moderna were worth $2,265,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp increased its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP grew its stake in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Moderna during the third quarter worth approximately $23,825,000. International Assets Investment Management LLC raised its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares during the last quarter. Finally, State of Michigan Retirement System grew its position in Moderna by 201.9% during the 2nd quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock worth $32,567,000 after acquiring an additional 183,407 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of MRNA stock opened at $41.83 on Monday. The stock has a market cap of $16.10 billion, a PE ratio of -7.19 and a beta of 1.58. The stock has a 50-day moving average of $48.26 and a 200-day moving average of $83.22. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.39) earnings per share. As a group, sell-side analysts expect that Moderna, Inc. will post -9.3 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,379 shares of company stock valued at $158,195. 15.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. cut their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Leerink Partners reduced their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $79.50.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.